Global Oncology Drug Advisory Mechanisms: Insights from FDA’s ODAC and International Counterparts

Advisory committees play a pivotal role in shaping oncology drug development, regulatory approvals, and patient access. The FDA’s Oncologic Drugs Advisory Committee (ODAC) is one of the most prominent examples of these mechanisms, providing independent expert recommendations on the safety, efficacy, and clinical benefit of cancer therapies. However, ODAC is not alone. Globally, similar structures, such as the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) advisory committees, contribute to oncology drug regulation in unique ways. This session offers an in-depth exploration of these mechanisms, their evolving processes, and their implications for the future of oncology drug development under changing regulatory leadership and global harmonization efforts.

Participants will gain a comprehensive understanding of ODAC’s structure, decision-making process, and real-world impact, illustrated through high-profile case studies. This session will also examine global parallels, comparing ODAC’s public transparency with the more closed-door approaches of CHMP and PMDA. Through a cross-comparison of advisory processes, we will explore differences in stakeholder engagement, such as the inclusion of patient advocates, and discuss how diverse regulatory pathways impact speed-to-market for oncology innovations.

Additionally, as administrations change and regulatory priorities shift, advisory committee processes are evolving. Emerging trends, such as the integration of real-world evidence, AI-assisted decision-making, and growing calls for global regulatory harmonization, are reshaping the landscape. These shifts bring opportunities to improve efficiency, inclusivity, and global collaboration in oncology drug approvals.

This session will leave participants equipped with actionable insights into advisory committee mechanisms worldwide, helping them anticipate regulatory changes, contribute to global alignment efforts, and position their organizations to navigate oncology drug development more effectively in an era of rapid transformation.